Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jeong Haeng Cho"'
Publikováno v:
Journal of Biological Engineering, Vol 18, Iss 1, Pp 1-12 (2024)
Abstract Background The use of single-chain variable fragments (scFvs) for treating human diseases, such as cancer and immune system disorders, has attracted significant attention. However, a critical drawback of scFv is its extremely short serum hal
Externí odkaz:
https://doaj.org/article/f6190c0324714d5ab25c6d715ffe904d
Autor:
Junyong Park, Mijeong Bak, Kiyoon Min, Hyun-Woo Kim, Jeong-Haeng Cho, Giyoong Tae, Inchan Kwon
Publikováno v:
Pharmaceutics, Vol 13, Iss 2, p 263 (2021)
Glucagon-like peptide-1 (GLP-1) is a peptide hormone with tremendous therapeutic potential for treating type 2 diabetes mellitus. However, the short half-life of its native form is a significant drawback. We previously prolonged the plasma half-life
Externí odkaz:
https://doaj.org/article/c69c61edea3b48d9ab3e7c537a1c0278
Autor:
Kiyoon Min, Hyun-Woo Kim, Inchan Kwon, Junyong Park, Giyoong Tae, Jeong-Haeng Cho, Mijeong Bak
Publikováno v:
Pharmaceutics
Pharmaceutics, Vol 13, Iss 263, p 263 (2021)
Volume 13
Issue 2
Pharmaceutics, Vol 13, Iss 263, p 263 (2021)
Volume 13
Issue 2
Glucagon-like peptide-1 (GLP-1) is a peptide hormone with tremendous therapeutic potential for treating type 2 diabetes mellitus. However, the short half-life of its native form is a significant drawback. We previously prolonged the plasma half-life
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5747d2d4240fdb582bc290b27058138
http://europepmc.org/articles/PMC7919490
http://europepmc.org/articles/PMC7919490